⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL196697 | 1.00 | — | — | |
| SCHEMBL3609296 | 1.00 | — | — | |
| SCHEMBL12361216 | 0.71 | MEN1 (0.33) | — | |
| SCHEMBL306399 | 0.69 | — | — | |
| SCHEMBL16926 | 0.69 | — | — | |
| SCHEMBL6999 | 0.69 | — | — | |
| SCHEMBL31741248 | 0.69 | — | — | |
| SCHEMBL4733761 | 0.69 | — | — | |
| SCHEMBL293705 | 0.69 | — | — | |
| SCHEMBL28773918 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014175444-A1 | ANTI-NLRR1 ANTIBODY | 千葉県 (JP) | 2014-10-30 | — | — | WO | disclosed |
| WO-2011112689-A9 | SALTS OF AN INDAZOLYLPYRROLOTRIAZINE | AMBIT BIOSCIENCES CORP. (US) | 2011-12-22 | — | — | WO | disclosed |
| WO-2011112689-A2 | SALTZ OF AN INDAZOLYLPYRROLOTRIAZINE | AMBIT BIOSCIENCES CORP. (US) | 2011-09-15 | — | — | WO | disclosed |
| US-20100029696-A1 | INDOLYLAMINO QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2010-02-04 | — | — | US | disclosed |
| US-20090137615-A1 | INDAZOLYLAMINO QUINAZOLINE DERIVATIVES AS ANTITUMOUR AGENTS | ASTRAZENECA AB (SE) | 2009-05-28 | — | — | US | disclosed |
| CN-101171245-A | Indolylamino quinazoline derivatives as antitumor agents | ASTRAZENECA AB (SE) | 2008-04-30 | — | — | CN | disclosed |
| CN-101171244-A | Indazolylaminoquinazoline derivatives as antitumor agents | ASTRAZENECA AB (SE) | 2008-04-30 | — | — | CN | disclosed |
| EP-1888590-A2 | CRYSTALLINE FORMS OF A PYRROLOTRIAZINE COMPOUND | Brystol-Myers Squibb Company (US) | 2008-02-20 | — | — | EP | disclosed |
| EP-1858885-A1 | INDOLYLAMINO QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | AstraZeneca AB (SE) | 2007-11-28 | — | — | EP | disclosed |
| EP-1858884-A1 | INDAZOLYLAMINO QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | AstraZeneca AB (SE) | 2007-11-28 | — | — | EP | disclosed |
| WO-2006135796-A3 | CRYSTALLINE FORMS OF A PYRROLOTRIAZINE COMPOUND | BRISTOL MYERS SQUIBB CO (US) | 2007-02-08 | — | — | WO | disclosed |
| US-20070015743-A1 | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | US | disclosed |
| WO-2006135796-A2 | CRYSTALLINE FORMS OF A PYRROLOTRIAZINE COMPOUND | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-12-21 | — | — | WO | disclosed |
| CN-1882572-A | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB (SE) | 2006-12-20 | — | — | CN | disclosed |
| WO-2006092574-A1 | INDOLYLAMINO QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2006-09-08 | — | — | WO | disclosed |
| WO-2006092573-A1 | INDAZOLYLAMINO QIONAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2006-09-08 | — | — | WO | disclosed |
| EP-1664029-A1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | AstraZeneca AB (SE) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005026152-A1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2005-03-24 | — | — | WO | disclosed |